A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-12-10

Summary

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

• Phase: PHASE2

Details

• Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• Treatments: Cyclophosphamide; fludarabine; Leucovorin; Methotrexate; Procarbazine; Rituximab; Temozolomide